Olpasiran

Phase 3RNA therapy

Amgen

Olpasiran is one of 58 small molecule programs targeting Cardiovascular Events. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cardiovascular EventsActive, not recruiting

Cardiovascular DiseaseRecruiting

Cardiovascular EventsPhase 3

Active, not recruiting

Cardiovascular DiseasePhase 3

Recruiting

Competition

Competitive Landscape

146 competitors in Cardiovascular Disease

#DrugCompanyPhaseTrials

Geodon

Primacor

Cardene

Sun Pharmaceutical Industries, Inc.

Approved

—4

Giapreza

LLa Jolla Pharmaceutical Company

Midamor

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

—7

Camzyos

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Colcrys

1 9

Cagrilintide

Novo Nordisk

Phase 3

1 10

Pelacarsen

Novartis

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 3Active, not recruiting

Cardiovascular Events

NCT05581303

Q2 2028

Phase 3Not yet recruiting

Cardiovascular Events

NCT07293260

Q4 2031

Phase 3Recruiting

Cardiovascular Disease

NCT07136012

Clinical

Trials by Indication[1]

Cardiovascular Events3 trials

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial

Not yet recruiting· Amgen logo

Amgen·Phase 3·NCT07293260·406 enrolled

Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study

Completed· Amgen logo

Amgen·Phase 2·NCT04270760·281 enrolled

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial

Active, not recruiting· Amgen logo

Amgen·Phase 3·NCT05581303·7,297 enrolled

Renal Impairment1 trial

A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Normal Renal Function and Participants With Various Degrees of Renal Impairment

Completed· Amgen logo

Amgen·Phase 1·NCT05489614·33 enrolled

ALS1 trial

A Study to Assess the Effect of Olpasiran on QT/QTc Intervals in Healthy Participants

Completed· Amgen logo

Amgen·Phase 1·NCT06411860·32 enrolled

Hepatic Impairment1 trial

A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Various Degrees of Hepatic Impairment

Completed· Amgen logo

Amgen·Phase 1·NCT05481411·25 enrolled

ESS1 trial

Olpasiran Expanded Access Program

Available· Amgen logo

Amgen··NCT07079267

2 more indications

Tics1 trial

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Olpasiran in Chinese Participants With Elevated Serum Lipoprotein(a)

Completed· Amgen logo

Amgen·Phase 1·NCT04987320·24 enrolled

Cardiovascular Disease1 trial

A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a)

Recruiting· Amgen logo

Amgen·Phase 3·NCT07136012·11,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Olpasiran. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Olpasiran compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Olpasiran. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Amgen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: RNA therapy[2]
Highest Phase: Phase 3[1]
Company: Amgen

Olpasiran

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q2 2028

Q4 2031

Trials by Indication[1]

Cardiovascular Events3 trials

Renal Impairment1 trial

ALS1 trial

Hepatic Impairment1 trial

ESS1 trial

Tics1 trial

Cardiovascular Disease1 trial

References

Drug Info

Quick Facts

Related News